General Partner
- Holger.Reithinger@forbion.com
- Download vCard 
Holger is a General Partner and Head of the Munich Office and joined Forbion in 2010.
Prior to that he was Principal and later Partner of Global Life Science Ventures, a well established life science-focused partnership with offices in Switzerland and Germany. He started in Venture Capital in 1997 as an Investment Manager at Technologieholding VC GmbH which at that time was the leading German Venture Capital firm. Technologieholding was acquired by the 3i Group in early 2000, where Holger became a Director at its Germany's healthcare practice.
Holger has served on the Boards of numerous life science companies including Epigenomics (IPO 2004), MBT (assets sold to Medigene AG), 4SC (IPO 2005), NeurogesX (IPO 2007), Fibrex Medical, Agendia and Santaris.
Before this, Holger gained operational experience as a product development manager at Biometra/WhatmanPlc (now part of GE Healthcare). He holds a PhD in Biochemistry, which he obtained on protein design under the supervision of Prof. Dr. Arne Skerra (founder of Forbion's portfolio company Pieris AG); all in the department of Prof. Dr. Hartmut Michel (Nobel Laureate 1988) at the Max-Planck-Institute of Biophysics. As an undergraduate, he studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich.
